Cellular Origins and Fresenius Kabi, an operating company of Fresenius, announce today they have signed a development agreement that leverages each company’s expertise in cell and gene therapies (CGTs ...
CAMBRIDGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced a ...
CAMBRIDGE, England & STEVENAGE, England--(BUSINESS WIRE)--Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), and ...
Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), today announced the acquisition of the ACTIA (Autologous ...
Cellular Origins reports that the company completed the first phase of its collaboration with Fresenius Kabi designed to help scale the manufacturing of cell and gene therapies using advanced robotics ...
In the intricate landscape of scientific exploration, researchers continue to probe the fundamental question of how life emerges from seemingly inert molecular structures. A pioneering Dutch research ...
Cellular Origins announces the completion of a USD 40 million (EUR 34.3 million) over-subscribed Series A round. The Series A financing was led by Johnson & Johnson, through its corporate venture ...
Cancers are diseases of abnormal cellular growth, and although many are treatable or even curable, their origins are not necessarily clear. Understanding the precise timing of cellular events—as cells ...
Cellular Origins, a TTP company, acquired the ACTIA (Autologous Cell Therapy Industrial Automation) Platform IP, developed by Geoff Hodge while CEO of SOTIO Biotech US. The ACTIA Platform complements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results